Amicogen, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023
November 14, 2023 at 03:08 am EST
Share
Amicogen, Inc. reported earnings results for the third quarter and nine months ended September 30, 2023. For the third quarter, the company reported sales was KRW 1,439.75 million compared to KRW 815.98 million a year ago. Net loss was KRW 273.62 million compared to net income of KRW 500.09 million a year ago. Basic loss per share from continuing operations was KRW 7 compared to basic earnings per share from continuing operations of KRW 12.5 a year ago. Diluted loss per share from continuing operations was KRW 7 compared to diluted earnings per share from continuing operations of KRW 12.5 a year ago. Basic loss per share was KRW 7 compared to basic earnings per share of KRW 12.5 a year ago.
For the nine months, sales was KRW 4,470.22 million compared to KRW 2,569.75 million a year ago. Net loss was KRW 1,524.85 million compared to KRW 19,324.84 million a year ago. Basic loss per share from continuing operations was KRW 38.5 compared to KRW 489 a year ago. Diluted loss per share from continuing operations was KRW 38.5 compared to KRW 489 a year ago. Basic loss per share was KRW 38.5 compared to KRW 489 a year ago.
Amicogen, Inc. is a Korea-based company engaged in the development, production and distribution of enzymes, bio new materials and healthcare food. The Companyâs products consist of special enzymes, N-acetylglucosamine (NAG), pinitol, D-Chiro-inositol (DCI), collagen peptides (CP) and protein A chromatography resins. The Company distributes its products within domestic market and to overseas markets, including China, Japan, the United Sates, Germany and Thailand.
AMICOGEN, INC. 
